{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:45:08Z","timestamp":1775018708795,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pulm Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s41030-025-00293-3","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T19:49:01Z","timestamp":1744141741000},"page":"269-283","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trial Conduct, Baseline Characteristics, and Symptom Burden of Patients in the ARISE Study"],"prefix":"10.1007","volume":"11","author":[{"given":"Charles L.","family":"Daley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chau-Chyun","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Korkut","family":"Avsar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Andrisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi Ruffo","family":"Codecasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayton W.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Laure","family":"Nevoret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Mange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"1","key":"293_CR1","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1186\/s12879-019-4078-0","volume":"19","author":"HJ Kim","year":"2019","unstructured":"Kim HJ, et al. Nontuberculous mycobacterial pulmonary disease diagnosed by two methods: a prospective cohort study. BMC Infect Dis. 2019;19(1):468.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"293_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","volume":"36","author":"DR Prevots","year":"2015","unstructured":"Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med. 2015;36(1):13\u201334.","journal-title":"Clin Chest Med"},{"key":"293_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","volume":"11","author":"CN Ratnatunga","year":"2020","unstructured":"Ratnatunga CN, et al. The Rise of Non-Tuberculosis Mycobacterial Lung Disease. Front Immunol. 2020;11:303.","journal-title":"Front Immunol"},{"issue":"3","key":"293_CR4","doi-asserted-by":"publisher","first-page":"1600537","DOI":"10.1183\/13993003.00537-2016","volume":"49","author":"JA Hwang","year":"2017","unstructured":"Hwang JA, et al. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J. 2017;49(3):1600537.","journal-title":"Eur Respir J."},{"key":"293_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jctube.2018.02.002","volume":"11","author":"T Kobayashi","year":"2018","unstructured":"Kobayashi T, et al. Change in lung function in never-smokers with nontuberculous mycobacterial lung disease: a retrospective study. J Clin Tuberc Other Mycobact Dis. 2018;11:17\u201321.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"4","key":"293_CR6","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1\u201336.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"293_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.chest.2023.06.014","volume":"164","author":"MR Loebinger","year":"2023","unstructured":"Loebinger MR, et al. Risk factors for nontuberculous mycobacterial pulmonary disease: a systematic literature review and meta-analysis. Chest. 2023;164(5):1115\u201324.","journal-title":"Chest"},{"key":"293_CR8","doi-asserted-by":"crossref","unstructured":"Aksamit T, et al. Refractory nontuberculous mycobacterial pulmonary disease: natural history and burden of illness in patients from the US bronchiectasis and NTM research registry (BRR). In: ID Week, Boston. 2023.","DOI":"10.1093\/ofid\/ofad500.1693"},{"issue":"1","key":"293_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.chest.2023.02.015","volume":"164","author":"E Henkle","year":"2023","unstructured":"Henkle E, et al. Patient-reported symptom and health-related quality-of-life validation and responsiveness during the first 6 months of treatment for Mycobacterium avium complex pulmonary disease. Chest. 2023;164(1):53\u201364.","journal-title":"Chest"},{"issue":"1","key":"293_CR10","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1136\/thoraxjnl-2014-205918","volume":"70","author":"AL Quittner","year":"2015","unstructured":"Quittner AL, et al. Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015;70(1):12\u201320.","journal-title":"Thorax"},{"key":"293_CR11","doi-asserted-by":"crossref","unstructured":"Mange K, et al. Psychometric validation of the QOL-B respiratory domain in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies. In: ISPOR, Atlanta. 2024.","DOI":"10.1016\/j.jval.2024.03.2019"},{"issue":"4","key":"293_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/NNR.0000000000000162","volume":"65","author":"S Ameringer","year":"2016","unstructured":"Ameringer S, et al. Psychometric evaluation of the patient-reported outcomes measurement information system fatigue-short form across diverse populations. Nurs Res. 2016;65(4):279\u201389.","journal-title":"Nurs Res"},{"key":"293_CR13","unstructured":"HealthMeasures. User manual and scoring instructions: PROMIS Fatigue. 2024. 29 May 2024 [cited 2024 10 July]. Available from: https:\/\/www.healthmeasures.net\/administrator\/components\/com_instruments\/uploads\/PROMIS%20Fatigue%20User%20Manual%20and%20Scoring%20Instructions_29May2024.pdf."},{"key":"293_CR14","doi-asserted-by":"crossref","unstructured":"Mange K, et al. Psychometric validation of the PROMIS fatigue-short form 7a in adults with newly diagnosed or recurrent Mycobacterium avium complex (MAC) lung disease: the ARISE and ENCORE studies. J Patient-Reported Outcomes. 2025 (In Revision).","DOI":"10.1016\/j.jval.2024.03.2075"},{"key":"293_CR15","doi-asserted-by":"crossref","unstructured":"Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964;2(5402): 177.","DOI":"10.1136\/bmj.2.5402.177"},{"issue":"2","key":"293_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1163\/157180994X00268","volume":"1","author":"J Legemaate","year":"1994","unstructured":"Legemaate J. The CIOMS guidelines for biomedical research involving human subjects. Eur J Health Law. 1994;1(2):161\u20135.","journal-title":"Eur J Health Law"},{"key":"293_CR17","unstructured":"ICH. Integrated addendum to ICH E6(R1): guideline for good clinical practice. ICH E6(R2). 2016 [cited 2024 11 July]. Available from: https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf."},{"issue":"2","key":"293_CR18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1378\/chest.13-1891","volume":"146","author":"AL Quittner","year":"2014","unstructured":"Quittner AL, et al. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014;146(2):437\u201348.","journal-title":"Chest"},{"issue":"1","key":"293_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s41687-019-0155-9","volume":"3","author":"SE Yount","year":"2019","unstructured":"Yount SE, et al. Responsiveness of PROMIS(R) to change in chronic obstructive pulmonary disease. J Patient Rep Outcomes. 2019;3(1):65.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"293_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s41687-019-0105-6","volume":"3","author":"CO Bingham Iii","year":"2019","unstructured":"Bingham Iii CO, et al. PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis. J Patient Rep Outcomes. 2019;3(1):14.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"293_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s41687-023-00645-0","volume":"7","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, et al. Qualitative and psychometric evaluation of the PROMIS(R)-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. J Patient Rep Outcomes. 2023;7(1):115.","journal-title":"J Patient Rep Outcomes"},{"issue":"10 Suppl","key":"293_CR22","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.apmr.2010.08.033","volume":"92","author":"JS Lai","year":"2011","unstructured":"Lai JS, et al. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch Phys Med Rehabil. 2011;92(10 Suppl):S20\u20137.","journal-title":"Arch Phys Med Rehabil"},{"issue":"1","key":"293_CR23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12890-020-1165-3","volume":"20","author":"N Kwak","year":"2020","unstructured":"Kwak N, et al. Longitudinal changes in health-related quality of life according to clinical course among patients with non-tuberculous mycobacterial pulmonary disease: a prospective cohort study. BMC Pulm Med. 2020;20(1):126.","journal-title":"BMC Pulm Med"},{"issue":"2","key":"293_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1378\/chest.13-2538","volume":"146","author":"RJ Wallace Jr","year":"2014","unstructured":"Wallace RJ Jr, et al. Macrolide\/Azalide therapy for nodular\/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014;146(2):276\u201382.","journal-title":"Chest"},{"issue":"2","key":"293_CR25","first-page":"243","volume":"8","author":"V Pravosud","year":"2021","unstructured":"Pravosud V, et al. Symptom burden and medication use among patients with nontuberculous mycobacterial lung disease. Chronic Obstr Pulm Dis. 2021;8(2):243\u201354.","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"1","key":"293_CR26","doi-asserted-by":"publisher","first-page":"1901300","DOI":"10.1183\/13993003.01300-2019","volume":"55","author":"E Henkle","year":"2020","unstructured":"Henkle E, et al. Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease. Eur Respir J. 2020;55(1):1901300.","journal-title":"Eur Respir J"},{"key":"293_CR27","unstructured":"Insmed Incorporated, Data On File; TR01\u2013112, Table 14.2.13.1."},{"issue":"9","key":"293_CR28","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1080\/13548506.2020.1808235","volume":"26","author":"T Kakuta","year":"2021","unstructured":"Kakuta T, et al. Prevalence of depressive symptoms and related risk factors in Japanese patients with pulmonary nontuberculous mycobacteriosis. Psychol Health Med. 2021;26(9):1172\u20139.","journal-title":"Psychol Health Med"},{"issue":"2","key":"293_CR29","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s12325-024-03064-9","volume":"42","author":"KP McCarrier","year":"2025","unstructured":"McCarrier KP, et al. Content validation of the QOL-B-RD and PROMIS-F SF-7a to measure respiratory and fatigue symptoms of MAC lung disease. Adv Ther. 2025;42(2):935\u201376.","journal-title":"Adv Ther"},{"issue":"11","key":"293_CR30","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","volume":"63","author":"D Cella","year":"2010","unstructured":"Cella D, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005\u20132008. J Clin Epidemiol. 2010;63(11):1179\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"5 Suppl 1","key":"293_CR31","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1097\/01.mlr.0000250483.85507.04","volume":"45","author":"BB Reeve","year":"2007","unstructured":"Reeve BB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the patient-reported outcomes measurement information system (PROMIS). Med Care. 2007;45(5 Suppl 1):S22\u201331.","journal-title":"Med Care"},{"issue":"11","key":"293_CR32","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, et al. General population norms for the functional assessment of chronic illness therapy (FACIT)-fatigue scale. Value Health. 2018;21(11):1313\u201321.","journal-title":"Value Health"}],"container-title":["Pulmonary Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41030-025-00293-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41030-025-00293-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T11:26:55Z","timestamp":1747999615000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41030-025-00293-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1007\/s41030-025-00293-3","relation":{},"ISSN":["2364-1754","2364-1746"],"issn-type":[{"value":"2364-1754","type":"print"},{"value":"2364-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Charles L. Daley: grant support, advisory board fees, and consulting fees from Insmed Incorporated. Dr. Daley also reports grant support from AN2 Therapeutics, Bugworks, Paratek Pharmaceuticals, Juvabis, FDA, NIH, PCORI, Cystic Fibrosis Foundation, COPD Foundation, and Renovion; advisory board work with AN2 Therapeutics, AstraZeneca, Cepheid, Galapagos, Hyfe, MannKind, Matinas Biopharma, NobHill, Spero Therapeutics, and Zambon; consulting with Galapagos, Genentech, and Pfizer; data monitoring committee work with Otsuka and Bill & Melinda Gates Foundation. James D. Chalmers: grant support from AstraZeneca, Boehringer Ingelheim, Genentech, Gilead Sciences, Grifols, GSK, Trudell, and Insmed Incorporated; consulting fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiese, Genentech, GSK, Insmed Incorporated, Pfizer, Trudell,\u00a0and Zambon. Patrick A. Flume: grant support and consulting fees from Insmed Incorporated. David E. Griffith: Consulting fees, personal fees, and advisory board fees from Insmed Incorporated. Dr Griffith also reports consulting and advisory board fees from AN2 Therapeutics and Paratek Pharmaceuticals. Naoki Hasegawa: consulting fees, advisory board fees, and clinical trial design or participation from AN2 Therapeutics and Janssen Pharmaceuticals; consulting fees, advisory board fees, and personal fees from Insmed Incorporated; consulting fees and clinical trial design or participation from MannKind. Kozo Morimoto: consulting fees, personal fees, and advisory board fees from Boehringer Ingelheim and Insmed Incorporated. Kevin L. Winthrop: grant support and consulting fees from AN2 Therapeutics, Insmed Incorporated, MannKind, Paratek Pharmaceuticals, Renovion, and Spero Therapeutics. Korkut Avsar: personal fees from Insmed Incorporated. Luigi Ruffo Codecasa: consulting fees from Cepheid and Dia Sorin. Chau-Chyun Sheu and Dario Andrisani have nothing to report. Dayton W. Yuen, Mariam Hassan, Marie-Laure Nevoret, and Kevin Mange are employees and shareholders in Insmed Incorporated. Charles L. Daley, James D. Chalmers, Patrick A. Flume, David E. Griffith, Naoki Hasegawa, Kozo Morimoto, Kevin L. Winthrop, Luigi Ruffo Codecasa, Chau-Chyun Sheu, Korkut Avsar, and Dario Andrisani were investigators in the ARISE trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"A data monitoring committee periodically monitored the safety of patients in the study. ARISE was approved by the Advarra Institutional Review Board under protocol reference number Pro00045468 on 12 August 2020. ARISE also received ethics approval from all study sites. Participants and\/or their legally authorized representative were informed that their participation was voluntary. Participants or their legally authorized representative were required to sign a statement of informed consent that met the requirements of 21 CFR 50, local regulations, ICH guidelines, HIPAA requirements. Participants did not consent for publication as no individual patient data are included. ARISE was conducted in compliance with its protocol and the ethical principles derived from international guidelines (Declaration of Helsinki, the Council for International Organizations of Medical Sciences International Ethical Guidelines), and applicable International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines, as well as applicable local laws and regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}